Fennec Pharmaceuticals Announces Pedmarqsi® Positive Recommendation by NICE for the Prevention of Cisplatin-Induced Hearing Loss in England and Wales

Stock Information for Marret Multi-Strategy Income Fund Class A

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marret Multi-Strategy Income Fund Class A

Fennec Pharmaceuticals Announces Investigator-Sponsored Trial to Be Conducted by City of Hope in Metastatic Testicular Germ Cell Tumors
Fennec Pharmaceuticals Announces Positive Topline Results From Investigator-Initiated Clinical Study of PEDMARK® in Japan to Reduce Cisplatin-Induced Hearing Loss
Fennec Pharmaceuticals to Participate in Piper Sandler 37th Annual Healthcare Conference
Fennec Pharmaceuticals Announces Completion Of Full Debt Redemption
Fennec Pharmaceuticals Announces Closing of Private Offering of Common Shares in Canada
Fennec Pharmaceuticals Announces Closing of Offering of Common Shares
Fennec Pharmaceuticals Announces Private Offering of Common Shares in Canada
Fennec Pharmaceuticals Announces Pricing of Offering of Common Shares

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.